Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
But how does it perform in the real world, among patients treated in the US?
And what is its activity in patients with BRCA mutations, PD-L1 positive disease, or prior exposure to sacituzumab govitecan (SG)?
We joined forces with Yale University to address this question in one of the largest studies to date (n=~1500).
– T-DXd exhibited favorable real-world activity for metastatic breast cancer (MBC).
– Compared with clinical trial outcomes, RW outcomes were consistent for patients with HER2-low MBC but worse for those with HER2-positive MBC
– Patients with TNBC and prior sacituzumab govitecan showed worse outcomes, highlighting significant cross-resistance between topoisomerase 1 ADCs
– Patients with BRCA mutations or with PD-L1-negative disease also showed worse outcomes with T-DXd, though based on relatively small numbers and warranting confirmation
Huge thanks to all the Dana-Farber Cancer Institute and Yale University RWD dream team that worked at this analysis, and Flatiron Health for providing the terrific dataset.”
Title: Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer
Authors: Paolo Tarantino, D. Lee, J. Foldi, P.R. Soulos, C.P. Gross, T. Grinda, E.P. Winer, N.U. Lin, I.E. Krop, S.M. Tolaney, M. Lustberg, S. Sammons
More posts featuring Paolo Tarantino on OncoDaily.
